Insmed (INSM) Just Drew Fresh Attention, So What Is The Market Missing?

American Century Investments Focused Dynamic Growth Fund recently exited its position in Insmed (INSM) after weaker than hoped uptake for key drug Brinsupri, a development that puts the biotech’s underlying commercial traction in sharper focus for investors.

Set against that setback, Insmed’s recent trading tells a mixed story, with a 32.25% 90 day share price return and a very large 3 year total shareholder return. This contrasts with a year to date share price decline of 26.94%, which signals fading momentum after an earlier surge.

Spot 39 healthcare AI stocks that, like Insmed, are trying to turn complex science into commercial traction, while sentiment and drug uptake remain under close watch.

Insmed now trades at a steep discount to both analyst targets and intrinsic estimates after that sharp pullback. Is this caution around Brinsupri uptake prudent, or is the market underpricing the pipeline and revenue base?

Most Popular Narrative: 34.4% Undervalued

Against Insmed's last close of $129.41, the most followed narrative pegs fair value at about $197.14. This frames the current pullback as a sizable valuation gap built on detailed launch, growth and margin assumptions.

The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3. The upcoming Phase II data for TPIP in PAH by mid-2025 and brensocatib in CRS without nasal polyps by the end of 2025 are key clinical milestones that could enhance future revenue streams if positive.

Read the complete narrative. Read the complete narrative.

Want to see what kind of revenue curve and profit swing analysts are including in their Insmed outlook to reach that fair value number? The narrative leans heavily on rapid top line expansion, a sharp pivot from losses to sizeable earnings, and a premium future multiple that is described as more like a fast growing software group than a typical biotech. Curious which assumptions around launch pacing, margin lift and long term valuation are seen as driving that gap between price and fair value?

Result: Fair Value of $197.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, two pressure points could quickly challenge the Insmed narrative: any delay or setback in Brinsupri approvals, and slower than expected real world uptake.

Find out about the key risks to this Insmed narrative.

Another View: What Insmed’s Sales Multiple Is Telling You

The DCF work presents Insmed as deeply undervalued, yet the market is already paying a rich P/S of 24.8x. That is about double the US Biotechs industry at 12.3x, roughly triple peer averages at 8x, and well above the fair ratio of 18.5x that the market could move toward. For investors, that gap points to potential valuation risk if aggressive revenue and margin assumptions do not fully materialize.

Our valuation checks walk through that sales multiple in detail and explain how it compares with sector norms and the fair ratio so you can assess whether the premium appears justified or stretched. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages in the Insmed story so far. Act while the facts are fresh in your mind, weigh both sides, and unpack the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Insmed?

If Insmed has sharpened your focus on where risk and potential might meet, do not stop here. Broader ideas can help balance conviction with caution.

• Scan for underappreciated quality by reviewing the 31 high quality undervalued stocks that may offer stronger fundamentals than their current prices suggest.
• Strengthen your downside protection and sleep easier by checking out the 11 resilient stocks with low risk scores that score well on resilience.
• Hunt for tomorrow's potential standouts early by researching the 16 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com